A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers

Trial Profile

A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
  • Indications Anal cancer; Cervical cancer; Oropharyngeal cancer; Penile cancer; Vulvovaginal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.
    • 18 Apr 2017 New translational data from this trial have been published in the journal Science, according to a Lion Biotechnologies media release.
    • 18 Apr 2017 Results published in a Lion Biotechnologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top